Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is developing CELx HSF test to diagnose two new sub-types of HER2-negative breast cancer. The company is also developing CELx MP test to diagnose 12 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, and bladder cancers. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone763-392-0767
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees26
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
Celcuity (NASDAQ:CELC) Frequently Asked Questions
What is Celcuity's stock symbol?
Celcuity trades on the NASDAQ under the ticker symbol "CELC."
How were Celcuity's earnings last quarter?
Celcuity Inc (NASDAQ:CELC) announced its earnings results on Tuesday, May, 7th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.04. View Celcuity's Earnings History.
When is Celcuity's next earnings date?
What price target have analysts set for CELC?
2 Wall Street analysts have issued 12-month target prices for Celcuity's stock. Their predictions range from $35.00 to $36.00. On average, they anticipate Celcuity's stock price to reach $35.50 in the next twelve months. This suggests a possible upside of 60.4% from the stock's current price. View Analyst Price Targets for Celcuity.
What is the consensus analysts' recommendation for Celcuity?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celcuity.
What are Wall Street analysts saying about Celcuity stock?
Here are some recent quotes from research analysts about Celcuity stock:
- 1. According to Zacks Investment Research, "Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular activity driving a patient's cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States. " (5/13/2019)
- 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $369M, which includes a discounted cash flow based asset value for CELx tests, with a 15% discount rate and 0.5% terminal growth rate. Probabilities of success assigned are 45% and 10% for breast cancer and colon cancer, respectively. Risks include, but are not limited to: (1) failure of CELx tests in clinical trials; (2) failure of CELx tests to secure CDx regulatory approval; and (3) failure of CELx tests to achieve commercial success due to market size, penetration rate, and/or competition." (12/10/2018)
Has Celcuity been receiving favorable news coverage?
News stories about CELC stock have trended somewhat positive on Wednesday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Celcuity earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Celcuity.
Are investors shorting Celcuity?
Celcuity saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 106,800 shares, an increase of 63.3% from the April 30th total of 65,400 shares. Based on an average daily volume of 6,400 shares, the short-interest ratio is currently 16.7 days. Approximately 2.1% of the shares of the stock are sold short. View Celcuity's Current Options Chain.
Who are some of Celcuity's key competitors?
Some companies that are related to Celcuity include RadNet (RDNT), Enzo Biochem (ENZ), Fulgent Genetics (FLGT), Miragen Therapeutics (MGEN), Psychemedics (PMD), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), Cancer Genetics (CGIX), CBA Florida (CBAI), First Choice Healthcare Solutions (FCHS), OpGen (OPGN) and Aeon Global Health (AGHC).
What other stocks do shareholders of Celcuity own?
Who are Celcuity's key executives?
Celcuity's management team includes the folowing people:
- Mr. Brian F. Sullivan, Co-Founder, Chairman & CEO (Age 57)
- Dr. Lance G. Laing, Co-Founder, Chief Science Officer, VP, Sec. & Director (Age 57)
- Ms. Vicky Hahne, Chief Financial Officer (Age 53)
- Ms. Laura Beggrow RN, Chief Commercial Officer (Age 56)
- Mr. Larry Fitzgerald, VP of Strategic Partnerships & Managed Markets (Age 48)
When did Celcuity IPO?
(CELC) raised $18 million in an IPO on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.
Who are Celcuity's major shareholders?
Celcuity's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Gagnon Securities LLC (1.68%), ARS Investment Partners LLC (0.69%), Accredited Investors Inc. (0.23%), Kessler Investment Group LLC (0.07%), Nelson Roberts Investment Advisors LLC (0.05%) and BNP Paribas Arbitrage SA (0.01%). View Institutional Ownership Trends for Celcuity.
Which institutional investors are selling Celcuity stock?
Which institutional investors are buying Celcuity stock?
CELC stock was acquired by a variety of institutional investors in the last quarter, including Nelson Roberts Investment Advisors LLC, Kessler Investment Group LLC and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Celcuity.
How do I buy shares of Celcuity?
Shares of CELC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celcuity's stock price today?
One share of CELC stock can currently be purchased for approximately $22.1267.
How big of a company is Celcuity?
Celcuity has a market capitalization of $225.91 million. The company earns $-7,480,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Celcuity employs 26 workers across the globe.View Additional Information About Celcuity.
What is Celcuity's official website?
How can I contact Celcuity?
Celcuity's mailing address is 16305 36TH AVENUE N SUITE 100, MINNEAPOLIS MN, 55446. The company can be reached via phone at 763-392-0767.
MarketBeat Community Rating for Celcuity (NASDAQ CELC)
MarketBeat's community ratings are surveys of what our community members think about Celcuity and other stocks. Vote "Outperform" if you believe CELC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELC will underperform the S&P 500 over the long term. You may vote once every thirty days.
